The investigational BTK inhibitor tolebrutinib did not lower the risk of confirmed disability progression compared with placebo in people with primary progressive multiple sclerosis (PPMS), failing to meet the main goal and several key secondary goals of the Phase 3 PERSEUS trial. It did, however, show signs of…
BTK inhibitor
Experimental Bruton’s tyrosine kinase (BTK) inhibitors, such as tolebrutinib or evobrutinib, are as effective as the approved therapy Aubagio (teriflunomide) at preventing relapses in people with relapsing forms of multiple sclerosis (MS), according to a review of published studies. The review found the therapies to be…
Recommended Posts
- With MS, parenting a teenager can get a little bloody — for dad
- Foralumab reduces microglial activity, inflammation in nonactive SPMS
- Living a full life as a mom with MS
- Living with MS puts me in the center of everything — literally and figuratively
- Ironically, cutting out coffee gave me a boost of energy